Related Experiment Video
Updated: Dec 12, 2025
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.8K
Cognitive Impairment Evaluation and Management
Lauren McCollum1, Jason Karlawish2
1Penn Memory Center, University of Pennsylvania, Philadelphia, PA, USA; Ralston House, Penn Memory Center, ATTN: Maria Crudele, 3615 Chestnut Street, Philadelphia, PA 19104-2612, USA.
The Medical Clinics of North America
|August 11, 2020
Summary
A systematic approach, including informant interviews and mental status exams, is crucial for evaluating cognitive impairment. This process guides diagnosis and informs essential treatment strategies for affected individuals.
Area of Science:
- Neurology
- Geriatrics
- Psychiatry
Background:
- Cognitive impairment is a growing concern in clinical practice.
- Accurate diagnosis is essential for effective patient management.
Purpose of the Study:
- To outline a systematic approach for evaluating cognitive impairment.
- To emphasize the importance of informant interviews and mental status examinations.
- To guide subsequent diagnostic work-up and treatment planning.
Main Methods:
- Systematic clinical evaluation.
- Informant interviews to gather collateral information.
- Thorough mental status examination to assess cognitive domains.
- Differential diagnosis based on impairment patterns.
Main Results:
- A structured approach identifies functional impairments and affected cognitive domains.
- The pattern of cognitive deficits guides the differential diagnosis.
- Diagnostic work-up is tailored based on initial findings.
Conclusions:
- A systematic evaluation is fundamental for diagnosing cognitive impairment.
- Interventions should address symptoms, with environmental, psychological, and behavioral strategies being key.
- Early and accurate diagnosis leads to more effective management plans.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
425
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
425
01:30Cognitive Development During Adulthood
626
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
626
01:30Dementia
414
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
414
01:26Alzheimer's Disease: Overview
1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
01:22Alzheimer's Disease: Treatment
648
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
648
01:25Cognitive Therapy
692
Cognitive therapy, pioneered by Aaron T. Beck in the 1960s, is a structured approach to addressing psychological distress by focusing on the influence of thoughts on emotions and behaviors. All cognitive therapies involve the basic assumption that human beings have control over their feelings, and that how individuals feel about something depends on how they think about it. Unlike psychoanalytic methods that delve into unconscious processes or humanistic approaches emphasizing...
692